COMPANY PROFILE / #1102
Evozyne
Chicago, ILVenture Capital-Backed
OVERVIEW
Operator of a data-driven evolution-based molecular engineering platform intended to create novel proteins with advanced functionality. The company's platform offers generative AI-driven design, experimental validation, iterative machine-learning refinement, and deep biological performance datasets, enabling pharmaceutical and biotechnology researchers to explore protein mechanisms, accelerate therapeutic discovery, and develop biologic treatments with enhanced specificity, stability and clinical potential.
已融资135.18
最新估值310.00
员工数54
成立年份2019
公司概况
- Companies
- Evozyne
- Description
- Operator of a data-driven evolution-based molecular engineering platform intended to create novel proteins with advanced functionality. The company's platform offers generative AI-driven design, experimental validation, iterative machine-learning refinement, and deep biological performance datasets, enabling pharmaceutical and biotechnology researchers to explore protein mechanisms, accelerate therapeutic discovery, and develop biologic treatments with enhanced specificity, stability and clinical potential.
- Website
- www.evozyne.com
- HQ Location
- Chicago, IL
- Year Founded
- 2019
- Keywords
- generative ai tools, healthcare market, molecular engineering, molecule drug, novel proteins, protein development, synthetic drugs
- Competitors
- Deep Genomics, A-Alpha Bio, AbCellera Biologics, GlycosBio, BellBrook Labs, ARVYS Proteins, Integrated DNA Technologies, Eurofins Genomics Europe Shared Services, Parexel International, LifeMine, Numaferm, Feldan Therapeutics, GATC Biotech, goBalto, Bio X Cell, GeneTex, ProMab Biotechnologies, ImageIQ, Cardior, Conagen, Arzeda, XtalPi Technology, Pacific Immunology, Abcam, ProSci (Biotechnology), Cypex, Eurofins Genomics Americas, Molecular Cloning Laboratories, Owkin, Adrenomed, Planet Biotechnology, Batavia Biosciences, Proteintech, c-LEcta, Origene, Centrillion Technologies, Valerius Biopharma, Paragon Bioservices, Advanced Proteome Therapeutics, JPT Peptides Technologies, Twist Bioscience, Genewiz, Resolian, GenWay BioTech, Codexis, CustomArray, Hyglos
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 135.18
- First Financing Date
- 01-Jan-2019
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 27-Sep-2023
- Last Financing Deal Type
- Early Stage VC
- Last Financing Size
- 81.00
- Last Financing Valuation
- 310.00
- Last Financing Status
- Completed
- Last Known Valuation
- 310.00
- Last Known Valuation Date
- 27-Sep-2023
- Last Known Valuation Deal Type
- Early Stage VC
- Valuation Estimate
- 364.79
- Valuation Estimate Growth Rate
- 17.68%
- Active Investors
- Fidelity, In-Q-Tel, NVentures (Santa Clara), Nvidia, OrbiMed, Paragon Biosciences, University of Chicago, Valor Equity Partners
- # Active Investors
- 8
- Acquirers
- —
团队与联系人
- Employees
- 54
- Employee Growth %
- -5.26%
- Employee History
- 2026: 54, 2025: 57, 2024: 60, 2023: 84, 2022: 63, 2021: 44, 2020: 25
- Primary Contact
- Patrick Morris
- Primary Contact Title
- Executive Officer & Board Member
- Primary Contact Email
- patrick.morris@evozyne.com
- Primary Contact Phone
- +1 (312) 847-1322
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- —
- Size Multiple
- —
- Size Multiple % Change
- —
- Size Multiple Change
- —
- Size Multiple Percentile
- —
- Majestic Referring Domains
- —
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 11%
- Success Probability Over Time – 3 Year
- 32%
- Success Probability Over Time – 5 Year
- 46%
记录来源：public.companies · 原始序号 #1102 · 所有字段均按数据库原值展示。